Portal de Periódicos da CAPES

Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observations a

1990; Wiley; Volume: 600; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1990.tb16919.x

1749-6632

G.A. Ricaurte, Kevin T. Finnegan, Ian Irwin, J. William Langston,

Neurotransmitter Receptor Influence on Behavior

Annals of the New York Academy of SciencesVolume 600, Issue 1 p. 699-708 Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observationsa G. A. RICAURTE, Corresponding Author G. A. RICAURTE Department of Neurology Johns Hopkins University School of Medicine Baltimore, Maryland 21205bAddress correspondence to: George A. Ricaurte, MD, PhD, Department of Neurology, Johns Hopkins Medical Institutions, 4940 Eastern Avenue, Baltimore, MD 21205.Search for more papers by this authorK. T. FINNEGAN, K. T. FINNEGAN Department of Psychiatry University of Utah School of Medicine Salt Lake City, Utah 84148Search for more papers by this authorI. IRWIN, I. IRWIN Institute for Medical Research San Jose, California 95128Search for more papers by this authorJ. W. LANGSTON, J. W. LANGSTON Institute for Medical Research San Jose, California 95128Search for more papers by this author G. A. RICAURTE, Corresponding Author G. A. RICAURTE Department of Neurology Johns Hopkins University School of Medicine Baltimore, Maryland 21205bAddress correspondence to: George A. Ricaurte, MD, PhD, Department of Neurology, Johns Hopkins Medical Institutions, 4940 Eastern Avenue, Baltimore, MD 21205.Search for more papers by this authorK. T. FINNEGAN, K. T. FINNEGAN Department of Psychiatry University of Utah School of Medicine Salt Lake City, Utah 84148Search for more papers by this authorI. IRWIN, I. IRWIN Institute for Medical Research San Jose, California 95128Search for more papers by this authorJ. W. LANGSTON, J. W. LANGSTON Institute for Medical Research San Jose, California 95128Search for more papers by this author First published: October 1990 https://doi.org/10.1111/j.1749-6632.1990.tb16919.xCitations: 66 a This work was supported in part by grant DA05938–01 from the National Institute on Drug Abuse, CPHF subcontract No. 019A-701 and NIH grant NS21011. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Peroutka, S. J. 1987. Incidence of recreational use of (±)3,4-methylenedioxymethamphetamine (Ecstasy) on an undergraduate campus. N. Engl. J. Med. 317(24): 1542–1543. 2 Siegel, R. K. 1985. Submitted as a preprint to the Drug Enforcement Agency for MDMA hearings. 3 Doblin, R. 1989. Risk Assessment, the FDA and MDMA Research. In Ecstasy: The MDMA Story. B. Eisner, Ed. Ronin Publishing, Inc., Berkeley , CA : pp. 163–170. 4 Schmidt, C. J. 1987. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240: 1–7. 5 Commins, D. L., G. Vosmer, R. Virus, W. Woolverton, C. Schuster & L. Seiden 1987. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241: 338–345. 6 Stone, D. M., D. S. Stahl, G. L. Hanson & J. W. Gibb 1986. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine on monoaminergic systems in the rat brain. Eur. J. Pharmacol. 128: 41–48. 7 Battaglia, G., S. Y. Yeh, E. O'Hearn, M. E. Molliver, M. J. Kuhar & E. B. DeSouza 1987. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242(3): 911–916. 8 O'Hearn, L., G. Battaglia, E. B. DeSouza, M. J. Kuhar & M. E. Molliver 1988. Methylenedioxyamphetamine (MDA) and methylenedioxy-methamphetamine (MDMA) cause ablation of serotonergic axon terminals in forebrain: Immunocytochemicl evidence. J. Neurosci. 8: 2788–2803. 9 Ricaurte, G. A., K. T. Finnegan, D. E. Nichols, L. E. DeLanney, I. Irwin & J. W. Langston 1987. (±)Methylenedioxyethylamphetamine (MDE) a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. Eur. J. Pharmacol. 137: 265–268. 10 Ricaurte, G. A., L. S. Forno, M. A. Wilson, L. E. DeLanney, I. Irwin, M. E. Molliver & J. W. Langston 1988. (±)3,4-Methylenedioxymethamphetamine (MDMA) selectively damages central serotonergic neurons in non-human primates. JAMA 260(1) 51–55. 11 Ricaurte, G. A., L. E. DeLanney, I. Irwin & J. W. Langston 1988. Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration. Brain Res. 446: 165–168. 12 Peroutka, S. J., N. Pascoe & K. F. Faull Monoamine metabolites in the cerebrospinal fluid of recreational users of 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). Res. Commun. in Substance Abuse 8: 125–138. 13 Price, L. H., G. A. Ricaurte, J. H. Krystal & G. R. Heninger 1988. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Arch Gen. Psych. 46: 20–22. 14 Hyyppa, M. T., H. Scheinin, H. Alaranta, M. Hurme, K. Lahtela & M. Scheinin 1985. Neurotransmission and the experience of low back pain: No association between CSF monoamine metabolites and pain. Pain 21(1): 57–65. 15 Barchas, J. & E. Usdin, Edss 1973. Serotonin and Behavior. New York : Academic Press Inc. 16 Lorens, S. A. 1978. Some behavioral effects of serotonin depletion depend on method. A comparison of 5,7-dihydroxytryptamine, p-chlorophenylalanine, p-chloroamphetamine and electrolytic raphe lesions. Ann. N.Y. Acad. Sci. 305: 532–555. 17 Messing, R. B. 1978. Behavioral effects of serotonin neurotoxins: An overview. Ann. N.Y. Acad. Sci. 305: 480–496. 18 Wurtman, R. J. 1987. Nutrients affecting brain composition and behavior. Integr. Psychiatry 5: 226–257. 19 Kilpatrick, I., M. Jones & O. Phillipson 1986. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: An isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem. 46(6): 1865–1876. 20 Pave S. 1986. Intranasal vasotocin decreases cerebrospinal fluid 5-HIAA levels in man. Brain Res. Bull. 16: 391–393. 21 Ben Menachem, E., L. Persson, P. J. Schecter, K. D. Haegele, N. Huebert & J. Hardenberg 1989. Cerebrospinal fluid parameters in healthy volunteers during serial lumbar punctures. J. Neurochem. 52: 632–635. 22 Sunderland, T., P. N. Tariot, R. M. Cohen, P. A. Newhouse, A. M. Mellow & E. A. Mueller 1987. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. Psychopharmacology 91: 293–296. 23 Pomara, N., R. Singh, D. Deptula, P. A. LeWitt, G. Bissette, M. Stanley & C. 'Nemeroff 1989. CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites. Biol. Psych. 26: 500–504. 24 Moir, A. T., G. W. Aschcroft, T. B. Crawford, D. Eccleston & H. Guldbert 1970. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain 93: 357–368. 25 Young, S. N., E. Garelis, S. Lal, J. Martin, P. Molina-Negro, R. Ethier & T. L. Sourkes 1974. Tryptophan and 5-hydroxyindoleacetic acid in human cerebrospinal fluid. J. Neurochem. 22: 777–779. 26 Mendels, J., A. Frazer, R. G. Fitzgerald, T. A. Ramsey & J. Stokes 1972. Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science 175: 1380–1382. 27 Asberg, M., P. Thoren & L. Traskman 1976. "Serotonin Depression"—a biochemical subgroup within the affective disorders? Science 191: 478–480. 28 Ashcroft, G., T. B. Crawford & D. Eccleston 1966. 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurologic diseases. Lancet 2: 1049–1050. 29 Bowers, M. B. 1974. Lumbar CSF 5-hydroxyindoleacetic acid and homovanillic acid in affective syndromes. J. Nerv. Ment. Dis. 158(5): 325–330. 30 Post, R. M., J. C. Ballenger & F. K. Goodwin 1980. Cerebrospinal fluid studies of neurotransmitter function in manic and depressive illness. In Neurobiology of Cerebrospinal Fluid. J. H. Wood, Ed. New York : Plenum Press, pp. 685–717. 31 Meltzer, H. Y. & M. Lowy 1987. The serotonin hypothesis of depression. In Psychopharmacology: The Third Generation of Progress. H. Meltzer, Ed. New York : Raven Press, pp. 513–526. 32 Post, R. M., J. Kotin, F. K. Goodwin & E. D. Gordon 1976. Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness. Am. J. Psychiatry 130: 67–72. 33 Eccleston, D., G. W. Ashcroft, T. B. Crawford, J. B. Stanton, D. Wood & P. H. McTurk 1970. Effect of tryptophan administration of 5-HIAA administration on 5-HIAA in cerebrospinal flaid in man. J. Neurol. Neurosurg. Psychiat. 33: 269–272. 34 Ricaurte, G. A., L. E. DeLanney, S. G. Wiener, I. Irwin & J. W. Langston 1988. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res. 474: 359–363. 35 Garelis, E., S. N. Young, S. Lal & T. L. Sourk 1974. Monoamine metabolites in lumbar CSF: The question of their origin in relation to clinical studies. Brain Res. 79: 1–8. 36 Weir, R. L., T. N. Chase, L. K. Ng, I. J. Kopin 1973 5-Hydroxyindoleacetic acid in spinal fluid: relative contribution from brain and spinal cord. Brain Res. 52: 409–412. 37 Stanley, M., L. Traskman-Bendz & K. Dorovin-Zis 1985. Correlation between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci. 37: 1279–1286. 38 Allen, S. J., J. S. Benton M. J. Goodhardt & E. A. Haan, N. R. Sims & C. T. Smith 1983. Biochemical evidence for selective nerve cell changes in the normal ageing human and rat brain. J. Neurochem. 41: 256–265. 39 Marcusson, J., L. Oreland, B. Winblad 1984. Effect of age on human serotonin S1 binding sites. J. Neurochem. 43: 1669–1705. 40 Goldman-Rakic, P. S. & R. M. Brown 1981. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 6: 177–187. Citing Literature Volume600, Issue1The Neuropharmacology of SerotoninOctober 1990Pages 699-708 ReferencesRelatedInformation